Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.44 - $2.01
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$54.23M
Enterprise Value$6.92M
Total Cash (Recent Filing)$2.50M
Total Debt (Recent Filing)$752.00K
Price to Earnings (P/E)0.2
Beta1.41
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.82
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda1.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet and conversion to an all-common equity structure materially improve financial flexibility and reduce default risk. This enables the company to allocate cash to lab automation, sales and R&D, supports a sustained operating turnaround and de-risks capital structure over the next several quarters.
Consistent Recent Cash GenerationPositive operating and free cash flow across 2023–2025, with strong FCF growth in 2025, indicates the business can internally fund operations and reinvestment. Sustained cash conversion reduces reliance on external capital and supports durable funding for growth initiatives and potential uplisting costs.
Strategic Pivot To Thyroid TestingThe full pivot to a focused thyroid diagnostics franchise concentrates resources on a higher-performing product set, simplifying operations and go-to-market focus. Clear 2026 revenue guidance tied to thyroid testing strengthens predictability and supports long-term market positioning and product specialization.
Bears Say
Uneven Revenue MomentumInconsistent top-line performance, including a revenue decline in 2025 after prior growth, raises concern about sustainable demand and market penetration. For a niche diagnostics firm, durable revenue growth is critical to absorb fixed lab costs and justify further automation or commercial investment.
Earnings-quality RiskA 2025 net margin that outpaces operating and EBITDA margins suggests results may include non-operating gains or one-offs, reducing confidence in recurring profitability. If earnings are not primarily operating-driven, cash sustainability and forecasting accuracy become more uncertain over the medium term.
Historic Balance-sheet And Cash VolatilityAlthough recently stabilized, the company’s history of negative equity and earlier multi-year negative cash flow signals execution risk and potential cyclicality. This track record means setbacks could quickly reintroduce liquidity pressure, making long-term financial resilience conditional on sustained operational improvement.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.44 and its highest was $2.01 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $54.23M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Mar 30, 2026. The company reported $0.818 earnings per share for the quarter, beating the consensus estimate of N/A by $0.818.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.818 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 13.855%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
―
bioAffinity Technologies, Inc.
―